Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $75.2 million.

  • Cytek Biosciences' Total Current Liabilities rose 1976.21% to $75.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.2 million, marking a year-over-year increase of 1976.21%. This contributed to the annual value of $67.7 million for FY2024, which is 2034.11% up from last year.
  • As of Q3 2025, Cytek Biosciences' Total Current Liabilities stood at $75.2 million, which was up 1976.21% from $73.3 million recorded in Q2 2025.
  • Cytek Biosciences' 5-year Total Current Liabilities high stood at $75.2 million for Q3 2025, and its period low was $28.2 million during Q2 2021.
  • In the last 5 years, Cytek Biosciences' Total Current Liabilities had a median value of $54.6 million in 2023 and averaged $52.6 million.
  • In the last 5 years, Cytek Biosciences' Total Current Liabilities surged by 5036.39% in 2022 and then tumbled by 226.16% in 2024.
  • Over the past 5 years, Cytek Biosciences' Total Current Liabilities (Quarter) stood at $33.2 million in 2021, then surged by 47.8% to $49.0 million in 2022, then increased by 14.65% to $56.2 million in 2023, then grew by 20.34% to $67.7 million in 2024, then increased by 11.15% to $75.2 million in 2025.
  • Its last three reported values are $75.2 million in Q3 2025, $73.3 million for Q2 2025, and $67.7 million during Q1 2025.